Dipharma
- Company typePrivate
- Founded1949
- HeadquartersBaranzate, Italy
- Headcount501–1,000
- GTM typeB2B
- OfferingHardware or Manufacturing
What Dipharma does
Dipharma Francis S.r.l. is a third-generation family-owned Italian Contract Development and Manufacturing Organization (CDMO) and manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company serves both innovator pharmaceutical companies (via custom synthesis/exclusive synthesis services for New Chemical Entities and difficult molecules such as heterocycles, small peptides, and natural products) and generic pharmaceutical companies (via a catalogue of generic APIs including Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid). It operates four cGMP manufacturing sites across Italy (Baranzate HQ, Mereto di Tomba, Caronno Pertusella) and the USA (Kalamazoo, MI), supported by two R&D centers and approximately 600 employees. Reported group revenue stood at approximately €160 million as of 2024.
The company's technical positioning is rooted in its 1949 civil-explosives heritage, which seeded distinctive competencies in handling hazardous chemistry — high-pressure hydrogenation (up to 40 bar and 220°C), batch and continuous nitration, nitroesterification, and azide chemistry — developed in strategic partnership with Biazzi SA, the engineering firm that owns the related continuous nitroglycerin process invented by founder Dr. Mario Biazzi. A team of 80+ R&D professionals (predominantly Masters and PhDs) operates proprietary process and analytical capabilities including a 15N-NMR method for nitrosamine impurity detection published in Organic Process Research & Development. Manufacturing capacity was materially expanded in 2023 with a second cGMP kilolab line at the US site (reactors up to 105 L, tripling capacity), and the company has secured FDA, ANVISA, and EU regulatory qualifications.
Revenue mechanics are split across two streams: (a) CDMO/Exclusive Synthesis services sold on a project-by-project contract basis with scope, complexity, and regulatory requirements driving quote-based pricing, and (b) Catalogue APIs and intermediates supplied to generic manufacturers under license/qualification terms with regulatory filings (EU DMF, CEP, US DMF, ANVISA CBPF, CADIFA) acting as the qualification-driven moat. Go-to-market is enterprise field sales via regional offices (Europe, North America, Japan, Rest of World) supplemented by heavy participation in industry events (CPHI, ChemOutsourcing, BIO, DCAT). The company does not disclose specific pricing tiers publicly; all engagement is contact-based.
Dipharma firmographics
Firmographics- Name
- Dipharma
- Legal name
- Dipharma Francis S.r.l.
- Website
- https://dipharma.com
- Company type
- Private
- Founded year
- 1949
- Operating status
- Operating
- Headcount range
- 501–1,000 employees
- Ownership category
- akta.pro rank
Dipharma industry classification
Industry- Product category
- Pharmaceutical API Manufacturing (CDMO)
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Medicinal Chemicals & Botanical Products (2833), Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Small-Molecule API & Intermediates CDMO (HLAGABAA)
- akta.pro secondary industries
- Chiral / Asymmetric Synthesis & Complex Chemistry Services (HLAGAHAE), GMP Scale-Up, Tech Transfer & Process Validation (PPQ) (HLAGAHAL), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Solid-State Chemistry & Preformulation (Polymorph/Crystallization) (HLAGAHAI), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Generic APIs & Intermediates (Active Ingredients) (HLAIABAG)
Keywords
Where Dipharma is headquartered
LocationHeadquarters
- HQ city
- Baranzate
- HQ country
- Italy
- HQ region
- Europe
Offices6 records
Markets served
Dipharma business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain, Marketing or Sales
Revenue model
- CDMO/Exclusive Synthesis Services: Contract development and manufacturing organization providing custom synthesis of difficult molecules, process route development and optimization, scale-up from early stage to commercial scale, analytical development, and solid state characterization services.
- Generic APIs and Intermediates: Manufacturing and supply of catalog active pharmaceutical ingredients for generic market. Includes advanced intermediates for pharmaceutical customers worldwide.
Go-to-market motion2 records
Distribution channels2 records
Marketing channels6 records
Dipharma product offering
Product offeringCore offering
Dipharma is a CDMO and manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for the pharmaceutical industry. It operates two business lines: Exclusive Synthesis (custom manufacturing of difficult molecules including heterocycles, small peptides, and natural products with process development and scale-up services from preclinical to commercial) and Catalogue APIs (portfolio of generic APIs such as Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid). The offering is supported by 4 cGMP manufacturing plants in Italy and the USA, two R&D centers, and proprietary hazardous chemistry capabilities.
Product overview
Dipharma is a global Contract Development and Manufacturing Organization (CDMO) and leading manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates. The company operates two core business lines: Exclusive Synthesis (custom synthesis/CDMO services) offering custom manufacturing of difficult molecules with process development and scale-up capabilities, and Catalogue APIs providing a portfolio of generic Active Pharmaceutical Ingredients. The offering is supported by cGMP manufacturing facilities including a Kilolab in Kalamazoo, MI (USA) and pilot plants in Italy (Mereto di Tomba and Caronno Pertusella), comprehensive R&D services from two fully-equipped R&D centers in Italy and USA, and technical white papers covering specialized topics such as nitrosamine risk control, azide chemistry, catalytic hydrogenation, and bile acid derivatives. Marketing collateral includes downloadable brochures for CDMO services and API portfolios.
Differentiator
Problem solved
Functional benefit
Products and services
- CDMO Services (Contract Development and Manufacturing Organization) Full-service Contract Development and Manufacturing Organization services offering custom synthesis, process route development, optimization, scale-up, and cGMP manufacturing of Active Pharmaceutical Ingredients from preclinical through commercial scale, for innovator and generic pharmaceutical companies.
- Exclusive Synthesis Custom synthesis services for difficult molecules including heterocycles, small peptides, and natural products, with process route development, optimization, scale-up to commercial scale, process impurity identification, safety assessment, and process chemistry re-design.
- Catalogue APIs (Generic APIs) Portfolio of generic Active Pharmaceutical Ingredients for the pharmaceutical market, including APIs such as Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid, with regulatory dossier support including EU DMF, CEP, US DMF, and ANVISA certifications.
- cGMP Kilolab Cutting-edge cGMP manufacturing suite located in Kalamazoo, MI (USA), providing API supply for clinical Phase 1 and early Phase 2, supported by a state-of-the-art cGMP Quality Control laboratory. FDA registered (FEI: 3004853226).
- cGMP Pilot Plants Small-scale cGMP pilot plants located at the Mereto di Tomba and Caronno Pertusella sites in Italy, offering full range of scale-up capabilities for early-stage drug development, clinical trials, and small production batches.
- R&D Services Research and development services including process research, supply chain evaluation, analytical research, process development, and process industrialization, backed by a team of 80+ skilled professionals and two R&D centers in Italy and the USA.
Quantifiable outcome
- 20% reduction in greenhouse gas emissions over past 5 years
- +2 more outcomes
Companies that use Dipharma
Customer profileNamed customers2 records
Segments2 records
Ideal customer profiles2 records
Dipharma technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Dipharma partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Biazzi SAcoreStrategic cooperation with Biazzi SA, the engineering company that leads the market in development and optimization of niche technologies, special equipment, and high-performance manufacturing complexes worldwide. Biazzi is the reference company for explosives, nitration, and hydrogenation technologies. Dipharma has historically adopted Biazzi hydrogenation equipment for highly efficient patented technology delivering low impurity levels. This partnership is essential for Dipharma's technological growth in complex chemical manufacturing.
Scale indicators11 records
Recent moves8 records
Expansion highlights6 records
Dipharma competitors and assessment
Company assessmentDirect peers
- CordenPharma: European CDMO with API manufacturing and drug delivery capabilities, owned by International Chemical Investors Group. Overlaps in complex peptide/small-molecule synthesis and specialty chemistry offerings.
- Hovione: Portuguese CDMO and API manufacturer with strong small-molecule process chemistry expertise and cGMP facilities in Europe, US and Asia. Direct competitor for custom synthesis and complex molecule development with similar hazardous chemistry capabilities.
- Aenova Group: Major European CDMO offering API manufacturing and finished dosage forms. Comparable as a mid-to-large private CDMO serving pharma customers across multiple regulatory jurisdictions.
- EuroAPI: European API manufacturer spun out from Sanofi, focused on generic APIs and CDMO services. Direct competitor in catalogue API supply with overlapping regulatory dossiers and customer relationships.
- Cambrex: US-based CDMO specializing in small-molecule API development and manufacturing across clinical and commercial phases. Comparable scale, capabilities, and customer overlap with Dipharma's US operations.
- Curia Global (formerly AMRI): Global CDMO providing API development, manufacturing, and formulation services for small molecules. Comparable scale and service offering with strong CDMO focus on both innovator and generic customers.
- Olon Group: Italian-headquartered generic API manufacturer with global manufacturing footprint supplying generics and CDMO services. Strong overlap with Dipharma's catalogue API business and Italian operational base.
- Sequens: European specialty CDMO/API manufacturer focused on small-molecule APIs and custom synthesis. Comparable positioning as a mid-sized European API/CDMO competitor with regulatory expertise.
Broad incumbents
- WuXi STA (WuXi AppTec): China-based global CDMO for small molecules and APIs with massive scale and integrated discovery-to-commercial services. Sets global pricing/competitive benchmarks for the CDMO industry despite being a much larger player.
- Fareva: Large privately-held French CDMO providing API, drug product, and specialty manufacturing services across multiple dosage forms. Broader portfolio than Dipharma but overlapping in API manufacturing and CDMO services.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights7 records
Customer concentration
Dipharma social profiles
Digital presenceDipharma compliance and trust
Trust signalCompliance7 records
Dipharma financial estimates
Financial estimateRevenue estimate
Valuation estimate
Dipharma leadership team
Management profileNumber of profiles
Profiles10 records
Dipharma subsidiaries and ownership
Company hierarchySubsidiaries1 record
Dipharma funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Dipharma M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Dipharma
What does Dipharma do?
Dipharma is a CDMO and manufacturer of Active Pharmaceutical Ingredients (APIs) and advanced intermediates for the pharmaceutical industry. It operates two business lines: Exclusive Synthesis (custom manufacturing of difficult molecules including heterocycles, small peptides, and natural products with process development and scale-up services from preclinical to commercial) and Catalogue APIs (portfolio of generic APIs such as Candesartan Cilexetil, Etripamil, Bupropion HBr, Letermovir, and Ursodeoxycholic Acid). The offering is supported by 4 cGMP manufacturing plants in Italy and the USA, two R&D centers, and proprietary hazardous chemistry capabilities.
Is Dipharma a public or private company?
Dipharma is a private company. It is classified as family owned and is currently operating.
When was Dipharma founded?
Dipharma was founded in 1949. It employs 501 to 1,000 people.
Where is Dipharma based?
Dipharma is headquartered in Baranzate, Italy, in the Europe region.
How does Dipharma make money?
Two revenue lines are on record. CDMO/Exclusive Synthesis Services are the primary driver. The others are generic APIs and Intermediates.
Who are Dipharma's main competitors?
Direct peers on record are CordenPharma, Hovione, Aenova Group, EuroAPI, Cambrex, Curia Global (formerly AMRI), Olon Group and Sequens. Broad incumbents are WuXi STA (WuXi AppTec) and Fareva.
Does Dipharma have an API?
No public API is recorded for Dipharma.
What industry is Dipharma in?
Dipharma's product category is Pharmaceutical API Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAA, Small-Molecule API & Intermediates CDMO, with a secondary code of HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services. Its NAICS code is 541714 and its SIC code is 2833.